- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Warburg Pincus completes acquisition of Bausch & Lomb
New York-Affiliates of private equity firm Warburg Pincus have completed the acquisition of Bausch & Lomb (B&L) for approximately $4.5 billion, including about $830 million of debt.
New York
-Affiliates of private equity firm Warburg Pincus have completed the acquisition of Bausch & Lomb (B&L) for approximately $4.5 billion, including about $830 million of debt.
“With a strong and supportive partner in Warburg Pincus, we are well-positioned to create new opportunities for [B&L] and advance our leadership in the eye health industry,” said Ronald L. Zarrella, chairman and chief executive officer of B&L, Rochester, NY.
Elizabeth H. Weatherman, a Warburg Pincus managing director, said, “We look forward to helping the company build upon its rich heritage and premier brand in ophthalmology.”
B&L stock has been delisted on the New York Stock Exchange. Under the terms of the acquisition agreement, B&L shareholders are entitled to receive $65 in cash for each share of B&L common stock that they hold.
